Salvia BioElectronics

Salvia BioElectronics is a clinical-stage medical device company developing a neurostimulation therapy for individuals suffering from chronic migraine.

The company's solution consists of a paper-thin, minimally-invasive implantable device that delivers gentle electrical pulses to the nervous system. Therapy is activated on-demand by the patient using an external, wearable device. This approach aims to provide a patient-centered treatment that can be used as needed to manage migraine symptoms.

The company operates in the healthtech and medical device market, specifically targeting the migraine therapy sector. Its business model is focused on the development and commercialization of this medical device. Having secured significant venture capital funding, including a $60 million Series B round, the company is progressing towards bringing its product to market, pending clinical trials and regulatory approvals. Revenue will likely be generated from the sale of the implantable device and the associated external activation system to healthcare providers and patients.

Keywords: neurostimulation, medical device, chronic migraine, bioelectronics, implantable, neuromodulation, healthtech, clinical-stage, therapy, patient-activated